Psychoactive Research chemicals are new synthetic substances that are structurally similar to the original drug, while being functional analogs. Research on the effects of, and treatment for, abuse of these drugs is limited due to the fact that they’re fairly new and have avoided mainstream notice. Research chemicals do not have a lot of human consumption data, and thus harm-reduction and special care should be taken if choosing to ingest them.
Psychedelics are drugs which cause profound changes in a one’s perceptions of reality, otherwise known as hallucinations. While under the influence of hallucinogens, users might see images, hear sounds or feel sensations. These chemicals offer some of the most intense psychological experiences and care should be taken when ingesting them.
Disclaimer: Psychedelic drugs offer some of the most power and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.
Practice Harm Reduction. Proceed with Caution.
Also known as:
- 1H-Indol-4-ol, 3-[2
-[methyl(1-methylet[ACD/Index Name] hyl)amino]ethyl]-
hyl)amino]ethyl}-1H[German][ACD/IUPAC Name] -indol-4-ol
hyl)amino]ethyl}-1H[ACD/IUPAC Name] -indol-4-ol
hyl)amino]éthyl}-1H[French][ACD/IUPAC Name] -indol-4-ol
-2-yl)amine)ethyl)-[ACD/IUPAC Name] 1 H-indol-4-ol
ETHYLETHYL)AMINO]ET HYL]-?1H-?INDOL-?4- ?OL
-2-yl)amino]ethyl]- 1H-indol-4-ol fumar ate
- 4-hydroxy MiPT
yl-N-methyltryptami ne fumarate
A reasonably popular tryptamine deriviative and Psilocin analogue, first synthesised by Alexander Shulgin. It has been reported as having comparable effects to psychedelic mushrooms, though with a shorter duration.
It is part of a series of psychedelic substituted tryptamines such as 4-AcO-DMT, 4-HO-MET, 4-HO-DiPT that are considered to produce variations of the core psychedelic effects typified by psilocin. This substance is relatively uncommon and has only a short history of human use. Alexander Shulgin evaluated its activity in humans in 1979, describing a trial of 12mg as a richly insightful and highly erotic experience.
A description of 4-HO-MiPT is included in Shulgin’s 1997 book TiHKAL. Shulgin’s trials and other anecdotal reports suggest that 4-HO-MiPT is similar in activity to psilocin, the active component in psilocybin mushrooms. Very little data exists about the pharmacological properties, metabolism, and toxicity of 4-HO-MiPT in humans.
As with psilocin, there have been no reported deaths from 4-HO-MiPT use despite the existence of reports of people taking doses which far exceeds the active dose. This suggests that it is well-tolerated physiologically. Today, 4-HO-MiPT is either used recreationally or as an entheogenic substance and is typically distributed as a grey-area research chemical by online vendors.
You can help by expanding it.
The first synthesis of 4-HO-MiPT was published in 1981 by a team of chemists led by David Repke. Repke and Shulgin later collaborated on a paper evaluating the effects of different oxygen substituents on the MiPT structure, describing 4-HO-MiPT as the most interesting of the series and the only one to possess classical hallucinogen effects.
Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R3 to an amino group via an ethyl side chain.
4-HO-MiPT is substituted at R4 of its indole heterocycle with a hydroxyl (HO) functional group OH-.
It also contains a methyl group and an isopropyl chain bound to the terminal amine RN of its tryptamine backbone (MiPT).
4-HO-MiPT is the N-substituted isopropyl homologue of 4-HO-DMT (Psilocin).
|Avg. Mass||232.3214 Da|
|Monoisotopic Mass||232.157562 Da|
|4-HO-MiPT Duration Data|
Interactions and Synergies
There are no existing interaction or synergy data for this drug.
|Effects||Brightened colors, visual distortions, altered perception, a sense of conectedness with the world around you, heightend emotions, paranoia, unwanted thoughts.|
|Marguis Test Result|
4-HO-MiPT’s psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
Disclaimer: The effects listed below are cited from the Subjective Effect Index (SEI), which relies on assorted anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be taken with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses (common+) are more likely to induce the full spectrum of reported effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.
- Sedation & Stimulation - 4-HO-MiPT is considered have the paradoxical property of both being relaxing, stoning and mildly sedating with a marked sense of physical stimulation that distinguishes it from related substances like psilocybin mushrooms or 4-AcO-DMT.
- Spontaneous physical sensations - The "body high" of 4-HO-MiPT can be described as a pleasurable, warm, soft, and all-encompassing tingling sensation. This maintains a consistent presence that steadily rises following the onset and hits its limit once the peak has been reached.
- Changes in felt bodily form - This effect is often accompanied by a sense of warmth or psychophysical unity and usually occurs around or directly after the peak of the experience. Users can feel as if they are physically part of or conjoined with other objects in a seamless continuity. This is usually reported as feeling comfortable, tranquil and mindful, though it can also manifest in the form of bodily tension.
- Changes in felt gravity
- Nausea - This effect can be greatly lessened or even completely avoided if the individual has an empty stomach prior to ingestion. It is sometimes recommended that one either refrain from eating for approximately 6 to 8 hours before-hand, or to eat a light meal 3 to 4 hours before if the user is feeling physically fatigued and undernourished. The nausea produced by 4-HO-MiPT is generally considered to be much less prominent than it is with psilocybin mushrooms, perhaps owing to the fact that there is no fungal-matter the body has to digest when the isolated synthetic form is consumed.
- Temperature regulation suppression - 4-HO-MiPT can cause fluctuates in the user's internal sense of temperature, which can manifest as sudden bouts of uncomfortable coldness or warmth, which is why a climate-controllable environment is strongly recommended in terms of a proper setting for a trip.
- Muscle contractions - The muscle contractions that can occasionally be produced by 4-HO-MiPT tend to be transient and benign feeling in nature, compared to many other tryptamines, phenethylamines and lysergamides.
- Olfactory hallucination
- Frequent urination
- Pupil dilation
- Increased salivation
- Excessive yawning - This effect seems to be uniquely pronounced among psilocin and related tryptamines. It can occur to a lesser degree on LSD and very rarely on psychedelic phenethylamines like mescaline. It typically occurs in conjunction with watery eyes.
- Watery eyes
- Teeth grinding - This component is considerably less intense when compared with that of substances like MDMA when it does happen to occur, but happens more readily than with related substances like psilocin or psilocybin, perhaps owing to the greater degree of stimulation it produces.
- Seizure - This is a likely a rare effect but may occur for those who are predisposed to them, especially while in physically taxing conditions such as being dehydrated, fatigued, undernourished, or overheated. However it should be noted that there are no documented cases of seizures occurring with this compound.
The cognitive effects of 4-HO-MiPT are described by many as extremely relaxing, profound and stoning in style when compared to other commonly used psychedelics such as LSD or 2C-B which tend to be energetic and stimulating. It contains a large number of typical and unique psychedelic cognitive effects. The most prominent of these typical effects generally include:
- Analysis enhancement
- Conceptual thinking
- Autonomous voice communication
- Déjà vu
- Emotion enhancement
- Enhancement and suppression cycles - This can be described as constant waves of extremely stimulated and profound thinking which are spontaneously surpassed in a cyclic fashion by waves of general thought suppression and mental intoxication. These two states seem to switch between each other in a consistent loop once every 20 - 60 minutes.
- Cognitive euphoria
- Increased libido
- Immersion enhancement
- Novelty enhancement
- Creativity enhancement
- Feelings of impending doom
- Increased sense of humor
- Increased music appreciation
- Memory suppression
- Personal bias suppression
- Thought connectivity
- Thought loops
- Time distortion
- Drifting (melting, breathing, morphing and flowing)
- Colour shifting
- Depth perception distortions
- Perspective distortions
- Symmetrical texture repetition
- After images
- Brightness alteration
The visual geometry that may be experienced can be described as more similar in appearance to that of psilocin, ayahuasca and 2C-E than LSD or 2C-B. It can be comprehensively described through its variations as intricate in complexity, abstract in form, organic in style, structured in organization, brightly lit and multicoloured in scheme, glossy in shading, soft in edges, large in size, slow in speed, smooth in motion, rounded in corners, non-immersive in depth and consistent in intensity. The visuals have a very "natural" feel to them and at higher dosages are significantly more likely to result in states of level 8B visual geometry over level 8A.
4-HO-MiPT and its various other forms produce a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics. These effects generally include:
- Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - This effect is very consistent in dark environments at appropriately high dosages. They can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
- External hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - These are more common within dark environments and can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
- Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.
It should be noted that these effects are reported to occur less reliably and impactfully than with the closely related psilocin or psilocybin, and generally require heavier doses to potentially induce. They are listed below as follows:
- Shulgin, Alexander. "Pharmacology Lab Notes #2". Lafayette, CA. (1976-1980). p312 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook2_searchable.pdf
- http://isomerdesign.com/PiHKAL/read.php?domain=tk&id=22 | 4-HO-MiPT (TiHKAL / Isomer Design)
- Repke, DB; Ferguson, WJ; Bates, DK. Psilocin analogs II. Synthesis of 3-[2-(dialkylamino)ethyl]-, 3-[2-(N-methyl-N-alkylamino)ethyl]-, and 3-[2-(cycloalkylamino)ethyl]indol-4-ols. J. Heterocycl. Chem., 1 Jan 1981, 18 (1), 175–179. 368 kB. http://dx.doi.org/10.1002/jhet.5570180131 | http://onlinelibrary.wiley.com/doi/10.1002/jhet.5570180131/abstract
- Repke, DB; Grotjahn, DB; Shulgin, AT. Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents. J. Med. Chem., 1 Jan 1985, 28 (7), 892–896. 711 kB. http://dx.doi.org/10.1021/jm00145a007 | http://pubs.acs.org/doi/abs/10.1021/jm00145a007
- Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. :10.1007/BF03161089. 1556-9039.
- List of controlled substances: Portaria SVS/MS nº 344 (Portuguese) | http://portal.anvisa.gov.br/lista-de-substancias-sujeitas-a-controle-especial
- "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 10, 2019.
- "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
- "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
- "Rozporządzenie Ministra zdrowia z dnia 21 sierpnia 2019 r. zmieniające rozporządzenie w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych" (PDF) (in Polish).
- Misuse of Drugs Act 1971 (Legislation.gov.uk) |http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I#reference-M_F_c7632653-ddad-4420-f307-e3da1e36d30e
- 1717 CheMall HE050097
- 1717 CheMall HE103448
- A&J Pharmtech AJ-83383
- ABI Chemicals AC2A05W8Q
- AK Scientific 9657AE
- AKos AKOS022182928
- Ark Pharm, Inc. AK-77115
- Aurora Fine Chemicals A06.998.030
- Aurora Fine Chemicals K05.595.152
- BGS International BG04556304
- Biosynth Carbosynth FH24436
- BLDpharm BD221974
- Cayman Chemical 11552
- Cayman Chemical 11552.0
- Cayman Chemical CM246846
- ChEMBL CHEMBL171419
- Chembo Pharma KB-72570
- Chemenu CM246846
- ChemIDplus 77872436
- EPA DSSTox DTXCID50150983
- Erowid 4-HO-MiPT
- FDA UNII - NLM 4GAJ9OJ8YZ
- Finetech Industry FT-0669668
- Journal of Heterocyclic Chemistry 19810175_15A
- LabNetwork LN01293210
- MuseChem R012879
- MuseChem R012880
- PubChem 10082683
- Syntharise Chemical SRISEC020
- Thomson Pharma 00533248
- VulcanChem VC059921
- VulcanChem VC059923
- Wikidata Q162772
- Wikipedia 4-HO-MiPT
Information made possible with:
- PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
- Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
- PubChem National Center for Bio Informatics
- Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
Additional APIs were used to construct this information. Thanks for ChemSpider, NCBI, PubChem etc.
Data is constantly updated so please check back later to see if there is any more available information on this substance.